Natera, Inc.
HealthcareNASDAQ:NTRA · NASDAQ Global Select
-$7.16 today
Vol 0.80M · Avg 1.41M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-12.2%
avg -126.3%
ROIC
-11.1%
avg -39.2%
ROA
-8.3%
avg -32.4%
Analysis
ROA is currently the strongest return metric at -8.3% versus its period average of -32.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Steven Leonard Chapman | Chief Executive Officer & Director | $1.98M | — | 47 | $135,640.00 | 0.09% |
Michael Brophy | Chief Financial Officer | $959,178.00 | — | 46 | $57,496.00 | 0.04% |
Matthew Rabinowitz | Co-Founder & Executive Chairman | $899,948.00 | — | 53 | $2.38M | 1.66% |
John Fesko | President & Chief Business Officer | $866,156.00 | — | 47 | $185,782.00 | 0.13% |
Solomon Moshkevich | President of Clinical Diagnostics | $866,156.00 | — | 44 | $138,841.00 | 0.10% |
Daniel Rabinowitz | Secretary & Chief Legal Officer | $610,606.00 | — | 57 | $2.38M | 1.66% |
Jonathan Sheena | Co-Founder & Director | $293,911.00 | — | 53 | $19,562.00 | 0.01% |
Olesya A. Anisimova | Chief Accounting Officer | — | — | — | — | — |
Rishi Kacker | Chief Technology Officer | — | — | — | — | — |
Phil Grinnell | Chief Sales Officer | — | — | — | — | — |
Jerry Diffley | Chief Compliance & Privacy Officer | — | — | — | — | — |
Eric A. Evans | Chief Scientific Officer | — | — | — | $2,129.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
155
$92.23M
Net Sentiment
$92.23M
Net selling
Most Active
Sheena Jonathan
35 transactions
1–10 of 155
Analysis
Insiders reported 0 buys worth $0.00 and 155 sells worth $92.23M over the last 12 months. That adds up to net selling of $92.23M. Sheena Jonathan was the most active insider with 35 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | +57.9% | +26.0% (14yr)7 analysts |
| Net Income | N/A | N/A | N/A | N/A7 analysts |
| EBIT | N/A | N/A | N/A | N/A7 analysts |
Analysis
Recent growth has been strongest in Revenue at +57.9% over three years. Forward estimates point to Revenue at +26.0% (14yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Teva Pharmaceutical Industries Limited
NYSE:TEVA
$40.32B
IQVIA Holdings Inc.
NYSE:IQV
$30.29B
DexCom, Inc.
NASDAQ:DXCM
$29.08B
Koninklijke Philips N.V.
NYSE:PHG
$25.70B
Illumina, Inc.
NASDAQ:ILMN
$24.35B
Waters Corporation
NYSE:WAT
$23.17B
BioNTech SE
NASDAQ:BNTX
$22.90B
Mettler-Toledo International Inc.
NYSE:MTD
$22.86B
Quest Diagnostics Incorporated
NYSE:DGX
$22.48B
STERIS plc
NYSE:STE
$20.26B
Who manages NTRA?
Natera, Inc. (NTRA) lists 12 active executives. The top listed executive is Matthew Rabinowitz, Co-Founder & Executive Chairman.
Are NTRA insiders buying or selling?
Recent insider activity shows net selling of $98.61M.
Explore More
Continue the stock analysis
Jump to another research area for this company.